News & Analysis as of

Patents › Japan › Pharmaceutical Patents

McDermott Will & Emery

[Webinar] IP Focus | US Patent Law Under the New Trump Administration - February 5th, 10:00 am JST

McDermott Will & Emery on

McDermott is committed to providing insightful commentary on intellectual property (IP) developments from around the world to our Japanese clients. During these sessions, a variety of speakers from McDermott’s offices in the...more

Hogan Lovells

Generic drugs taking hold in the Asian marketplace: STAT News interview

Hogan Lovells on

Aging populations and rising healthcare costs across Asia — particularly in Japan — have created new market opportunities for generic drug makers operating in the region. For originator drug manufacturers, that means...more

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Biosimilar Uptake and Patent Litigation in Japan

Sterne, Kessler, Goldstein & Fox P.L.L.C. on

Biosimilar uptake in Japan has been a bit mixed, but according to experts the volume shares of biosimilars suggests it could be a key market in years to come. The Pharmaceuticals and Medical Devices Agency (PMDA), which is...more

Dorsey & Whitney LLP

US China Trade War — Stock Market Crash, Presidential Trade Politics, Trade Policy, Customs, Antitrust and Securities

Dorsey & Whitney LLP on

The Chinese stock market crash and world- wide effect on stock markets around the World has created a crisis with day to day developments. The World Stock market crash stated on August 24, 2015 and went through to August...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide